Vaccinex (NASDAQ:VCNX) Shares Up 12.5% – What’s Next?

Vaccinex, Inc. (NASDAQ:VCNX) rose 12.5% during mid-day trading on Tuesday . The stock traded as high as $1.1245 and last traded at $1.1245. Approximately 213 shares were traded during trading, a decline of 92% from the average daily volume of 2,663 shares. The stock had previously closed at $1.00.

Vaccinex Stock Performance

The company has a market capitalization of $2.92 million, a price-to-earnings ratio of -0.02 and a beta of 1.10. The stock’s 50-day moving average price is $0.75 and its 200-day moving average price is $0.71.

Vaccinex Company Profile

Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.

In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.